The safety and efficacy of Glubran 2 as biliostatic agent in liver resection
| Autor: | Mauro Piccirillo, Guglielmo Nasti, Vincenza Granata, Roberta Fusco, Antonio Avallone, Francesco Izzo, Andrea Belli, Vittorio Albino, Raffaele Palaia, Renato Patrone, Fabiana Tatangelo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Efficacy Epidemiology medicine.medical_treatment Group A lcsh:RC254-282 Group B law.invention lcsh:Infectious and parasitic diseases 03 medical and health sciences Liver metastases 0302 clinical medicine law medicine Chemotherapy lcsh:RC109-216 Adverse effect Bile duct injury business.industry Biliary fistula medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hepatic resection Surgery Infectious Diseases Oncology Cyanoacrylate 030220 oncology & carcinogenesis Population study 030211 gastroenterology & hepatology Complication business Research Article |
| Zdroj: | Infectious Agents and Cancer, Vol 16, Iss 1, Pp 1-7 (2021) Infectious Agents and Cancer |
| ISSN: | 1750-9378 |
| Popis: | Background Biloma, an encapsulated collection of bile outside the biliary tree, supported by a predominantly iatrogenic biliary fistula, and bile likeage are two of the most important surgical complications after liver resection. We, hypothesized to conduct a project aimed to prevent, or reduce, the formation of biloma or biliary fistula applying on the hepatic resection area the cyanoacrylate glue (Glubran2). Methods We searched in our surgical database all patients underwent liver resection for mCRC from January 2013 to December 2018 and we found a total of 510 patients. 205 patients for Group A (study population: included patients in which we have used Glubran2 during surgical procedure) and 113 patients for Group B (control group), were enrolled. Results In both Groups no patients died during hospitalization and the 30-day mortality was 0 %. During follow-up in Group A, a biliary fistula was found in 2 patients (1 %) versus 3 patients in the Group B (2,6 %). In patients enrolled in Group A no adverse event were reported relate to the use of Glubran2. Conclusions It is possible to affirm that the use of Glubran2 as biliostatic agent after liver resection is useful to prevent bile leakage complication and biloma formation and its use demonstrated to be safe and feasible during liver surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|